Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CAMT heads into its November 10 earnings report with short sellers maintaining elevated positions, borrow conditions easing, and the stock nursing a sharp weekly loss that has stretched the gap to analyst price targets.
The most striking tension this week is between a short position that remains structurally large and a borrow market that is quietly loosening. Short interest holds at 8.3% of the free float, a level that has crept up roughly 3.3% over the past month. That is a meaningful short book for a semiconductor equipment name. Yet the borrow market tells a different story: availability has jumped sharply, rising 36% on the week to 83.8%, meaning there is now considerably more room in the lending pool than there was just days ago. As recently as October 2, availability had tightened to around 10.5%, close to the 52-week low of 0.2% reached in mid-September, when the lending pool was nearly exhausted. Cost to borrow has been drifting lower too, down roughly 10% on the week to 3.0%, and off more than 22% from a month ago when it was running above 4.4%. Short sellers are not being squeezed out. If anything, fresh shorts face an easier entry than at any point in the past six weeks. Options positioning is broadly neutral: the put/call ratio of 0.69 sits almost exactly in line with its 20-day average, with a z-score near zero, suggesting no unusual hedging demand around the price weakness.
The Street remains structurally bullish but has been trimming its ambition. Morgan Stanley's Shane Brett cut his target a second time in two months, moving to $152 from $165 on September 28, while keeping an Equal-Weight rating. That target is now only 7% above the current price of $142.78, the narrowest cushion it has been in some time. The broader consensus mean sits at $182.70, implying around 28% upside from current levels, with Buy-rated houses including Jefferies (target $200) and Evercore ISI (target $200) still well above the tape. Stifel downgraded to Hold back in April and has not moved since. Valuation multiples give some context for the disagreement: the stock trades at roughly 31.5 times trailing earnings and 27 times EV/EBITDA, with the EV/EBITDA multiple having compressed about 1.6 turns over the past month as the share price has pulled back. The forward earnings picture is one reason bulls stay engaged: the 12-month forward EPS estimate growth ranks in the 87th percentile of the ORTEX universe. The ORTEX short score has been parked in the mid-70s all month, ranking in the bottom 2nd percentile for its sector, a reading consistent with a stock where bearish signals cluster.
The ownership structure deserves a mention because it shapes how freely the float can trade. Two strategic shareholders, Priortech Ltd and Chroma ATE Inc., together hold about 37% of shares outstanding and have not moved their positions in recent filings. That concentrates the effective free float and goes some way to explaining why availability can swing so dramatically: when institutions lend and recall shares, the effect on a smaller tradeable pool is amplified. Among the 13D/G register, Migdal Insurance raised its stake to 8.33% from 5.1% as of July, and Harel Insurance moved to 7.8% from 5.3% in May, both passive holders adding exposure. Wasatch Advisors, by contrast, has trimmed below the 5% reporting threshold. Stakes here are as-last-disclosed around the 5% threshold, and holders dropping below that level may not file again. On the insider side, the 90-day net from SEC Form 4 filings shows net selling of about $5.1 million, with the CEO, COO, and CFO all recording open-market sales in August at prices between $164 and $175, well above today's level.
Wikipedia attention, a measure of retail interest tracked by ORTEX against the stock's own 90-day history, produced a z-score of 5.2 as of late September, one of the more elevated readings across names covered. That spike in attention coincided with the post-earnings rally in August, when the stock jumped more than 10% on the day of results. The five-day follow-through from that print was slightly negative, down about 1.4%, suggesting the initial gap was not fully sustained.
With earnings due November 10 and the stock now trading about 18% below the August post-results high, the question heading into that print is whether the borrow market's recent loosening reflects genuine short covering or simply a technical reset after a period of extreme tightness, and whether the Street's divided targets converge or diverge further depending on what management says about the advanced packaging cycle.
See the live data behind this article on ORTEX.
Open CAMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
